The impact of the combination of the GLP-1 analogue liraglutide (Victoza) and laparoscopic adjustable gastric banding (LAGB) on diabetes control.

Trial Profile

The impact of the combination of the GLP-1 analogue liraglutide (Victoza) and laparoscopic adjustable gastric banding (LAGB) on diabetes control.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Aug 2014

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms GLIDE
  • Most Recent Events

    • 17 Jul 2014 Status changed from recruiting to discontinued as reported by United Kingdom Clinical Research Network.
    • 18 Oct 2013 Planned end date changed from 1 Sep 2015 to 1 Jun 2016 as reported by United Kingdom Clinical Research Network.
    • 04 May 2013 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top